BIOMAT Database Logo BIOMAT Database Logo

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 1998

R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Department of Pediatrics and Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA.

OBJECTIVE The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 300 assessed the clinical efficacy and safety of combination zidovudine/lamivudine (ZDV/3TC) compared with either didanosine (ddI) alone or combination ZDV/ddI. METHODS Children with symptomatic human immunodeficiency virus (HIV) infection, 6 weeks through 15 years of age, were stratified according to age and randomly assigned to receive ddI, ZDV/3TC, or ZDV/ddI. The primary endpoint was time to first progression of HIV disease or death. Enrollment in the ZDV/ddI arm stopped after 11 months on the basis of results of PACTG Protocol 152, but blinded follow-up continued. RESULTS For the 471 children who could be evaluated, the median age was 2.7 years, median CD4 cell count was 699 cells/mm3, and median log10 HIV RNA was 5.1/mL. Median follow-up was 9.4 months. Patients receiving ZDV/3TC had a lower risk of HIV disease progression or death than those receiving ddI alone (15 vs 38 failures, P = .0006) and a lower risk of death (3 vs 15 deaths, P = .0039). Weight and height growth rates, CD4+ cell counts, and RNA concentrations showed results favoring ZDV/3TC. For patients concurrently randomized to all 3 treatment arms, both ZDV/3TC and ZDV/ddI recipients had lower risk of HIV disease progression than those who received ddI alone (P = .0026 and P = .0045). CONCLUSIONS Combination therapy with either ZDV/3TC or ZDV/ddI was superior, as determined by clinical and laboratory measures, to monotherapy with ddI.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
June 1997, The New England journal of medicine,
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
November 1999, Journal of acquired immune deficiency syndromes (1999),
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
June 2001, Journal of acquired immune deficiency syndromes (1999),
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
July 1996, JAMA,
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
December 1998, AIDS research and human retroviruses,
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.
March 2000, AIDS research and human retroviruses,
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
June 1996, Annals of internal medicine,
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
April 1999, AIDS (London, England),
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
May 1995, Archives of internal medicine,
R E McKinney, and G M Johnson, and K Stanley, and F H Yong, and A Keller, and K J O'Donnell, and P Brouwers, and W G Mitchell, and R Yogev, and D W Wara, and A Wiznia, and L Mofenson, and J McNamara, and S A Spector
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
September 2000, Antiviral therapy,
Copied contents to your clipboard!